MDB Capital's Value-Inflection Pivot: From IPO Launches to Core-Asset Monetization
Amid a 76% drawdown, MDB refocuses on four key holdings, a leaner cost base, and avoiding dilution.
MDBH · Earnings Call · 2026-08-13
Strategic Pivot
MDB Capital has long been a microcap IPO factory, but this quarter's call makes clear the model is shifting. CEO Chris Marlett openly acknowledged the stock's collapse and the sector's desolation: “We're not happy with where we're at.” The new emphasis is on value inflection — a term that jumped into the company's own top keyword list in 20262 — and on monetizing the core four assets: Public Ventures, PatentVest, eXoZymes, and Paulex Bio. This is not the first time management has talked about these assets, but the tone and tactical plan have changed.
We're not looking to raise more money. We're not looking to go out and spend more money. … We just need to monetize and leverage the ones that we've done and take a very, go back to a rifle-shot approach until the environment is better for what we do.
Monetizing Core Assets
The most concrete moves involve the two wholly-owned subsidiaries. Public Ventures, the self-clearing brokerage, is being shopped: “We're looking to partner it with somebody else out there that has a broader platform.” Management says they have multiple counterparties and an LOI in hand, aiming to wrap something in the next quarter. Meanwhile, PatentVest is being spun out as an independent entity, leveraging its patent lawyers and an Arizona ABS license to become the “law firm of the future.” The pivot to AI-driven patent prosecution is a deliberate response to a market where legal tech valuations have exploded.
On eXoZymes, the message is about commercial traction finally arriving: “They are very close to executing a relationship with contract manufacturers … that could effectively make all of the small molecules that they're developing.” This is the long-promised manufacturing proof point that could unlock commercial deals. Paulex Bio, the last core asset, is nearing an IPO and has data expected in early 2027 on beta-cell expansion — a potential game-changer in diabetes care.
Financial Discipline and Leverage
The company's fundamentals reflect the strain: Operating income was -$6M in the latest quarter, with a full-year trend that is stabilizing after a severe dip in 2024. Management's target is to run the platform on $5-6M per year, offset by fee income from a few deals. This is a repeat of earlier promises, but the spin-out of PatentVest and the partnership of Public Ventures would remove two cost centers, making the target more credible.
The lot of leverage embedded in MDB's share count is the central thesis: with roughly 10 million shares outstanding, even a single holding reaching $1 billion — as eXoZymes or Paulex could theoretically do — would be transformative. The company is explicitly betting that the market is mispricing this optionality.
What Changed and Why It Matters
The change is not the narrative (leverage without dilution has been a staple) but the execution: a clear decision to stop scaling launches, cut costs, and force the four assets to their own inflection points. Prior calls telegraphed the PatentVest spin-out and a distribution philosophy, but now the timeline is tighter, and the tone is more urgent. As Marlett said on the current call, “everything is on track to our knowledge with clinical trial” for Paulex — a sharp contrast to prior hedging.
The stock is trading at $3.27, down 76% from its 2024 peak, and the 90-day trend is still down. Yet the company is pointing to specific, datable catalysts: a Public Ventures deal, a PatentVest financing, eXoZymes manufacturing partnerships, and Paulex's IPO. If any one hits, the leverage is real; if none do, the drawdown continues. This is a company-unique, binary setup with clear evidence of a strategic pivot.